LH Longevity-Medicine Target Ranges: What Optimal Looks Like Beyond "Normal"

What LH Actually Measures and Why Longevity Clinicians Care

LH is a glycoprotein released in pulses by the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) from the hypothalamus. In men, LH binds Leydig cells to stimulate testosterone synthesis. In women, the mid-cycle LH surge triggers ovulation, and basal LH regulates estradiol production in the follicular phase.

Standard laboratory reference intervals are built on population statistics, not on health optimization. They capture the middle 95 percent of whoever walked through the lab door, including people with obesity, metabolic syndrome, poor sleep, and subclinical pituitary dysfunction. Longevity medicine uses those intervals as a floor, not a ceiling.

Why the HPG Axis Declines With Age

Testosterone declines roughly 1 to 2 percent per year in men after age 30, a process called late-onset hypogonadism [1]. As Leydig cell mass and responsiveness fall, LH rises in compensation. A man whose testosterone reads 320 ng/dL (technically "normal" by many labs) with an LH of 8.9 IU/L is showing clear pituitary strain. That pattern tells a different story than the same testosterone reading paired with an LH of 4.2 IU/L.

In women, the perimenopause transition produces rising FSH and LH as ovarian reserve depletes. The Stages of Reproductive Aging Workshop (STRAW+10) defined menopause-transition staging using FSH thresholds above 25 IU/L on two occasions, with LH trending upward in parallel [2].

LH Pulsatility: What a Single Draw Misses

LH is secreted in pulses every 60 to 120 minutes. A single serum draw captures one moment in that cycle and may over- or under-estimate the pituitary's true output by 20 to 40 percent. Morning draws (before 10 a.m.) reduce intra-individual variability in men. Serial sampling or multiple draws 20 to 30 minutes apart improves accuracy when clinical suspicion is high [3].

Standard Reference Ranges vs. Longevity-Medicine Targets

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism defines biochemical hypogonadism as total testosterone below 264 ng/dL on two fasting morning samples [4]. LH interpretation is mandatory at that threshold: a low or inappropriately normal LH points to secondary (central) hypogonadism requiring pituitary MRI, while an elevated LH confirms primary gonadal failure.

Interpreting Low LH With Low Testosterone

Secondary hypogonadism accounts for approximately 40 percent of hypogonadism cases in men seeking care at endocrine practices [5]. Common causes include:

• Obesity and insulin resistance (hypothalamic GnRH suppression)
• Exogenous androgen use (feedback suppression of LH to near zero)
• Opioid use (centrally suppresses GnRH pulsatility)
• Hyperprolactinemia (prolactin directly inhibits GnRH)
• Pituitary adenoma or infiltrative disease

A man using testosterone cypionate 200 mg every two weeks will typically show LH <0.5 IU/L due to negative feedback. This is expected and not pathological in the context of prescribed TRT, but it does confirm that endogenous testicular stimulation has ceased, making fertility preservation (hCG co-treatment) a clinical discussion.

Interpreting High LH

Persistently elevated LH in men above 9 to 10 IU/L, especially when paired with low-to-low-normal testosterone, confirms that the testes are failing to respond to adequate pituitary drive. This pattern appears in Klinefelter syndrome (47,XXY), mumps orchitis sequelae, radiation injury, and age-related primary hypogonadism. The EMAS (European Male Aging Study) of 3,369 men found that symptomatic late-onset hypogonadism required both a testosterone below 11 nmol/L (317 ng/dL) and the presence of at least three sexual symptoms [6].

LH in Women: Cycle Phase Is Everything

A single LH value drawn without cycle-phase documentation is nearly uninterpretable. Follicular-phase LH governs estradiol production. The pre-ovulatory surge, peaking 24 to 36 hours before egg release, is the most diagnostically rich event in the cycle.

Detecting the LH Surge for Fertility and Ovulation Confirmation

Urine LH strips detect the surge 12 to 24 hours before ovulation. Serum LH drawn on cycle day 2 to 3 (follicular baseline) and again at suspected ovulation provides a more complete picture. A mid-cycle serum LH below 8.7 IU/L in a woman reporting regular cycles raises suspicion for anovulation, warranting progesterone measurement on day 21 to 23 [7].

In women pursuing fertility treatment, LH monitoring guides trigger timing. In GnRH-antagonist IVF protocols, premature LH surges above 10 IU/L before the dominant follicle reaches 17 to 18 mm require immediate antagonist adjustment.

LH and Polycystic Ovary Syndrome (PCOS)

An LH-to-FSH ratio above 2:1 (often 3:1) on a cycle day 2 to 3 draw is a classic finding in PCOS, present in roughly 40 to 60 percent of affected women [8]. The elevated LH drives excess androgen production from theca cells. The 2023 international evidence-based PCOS guideline (co-authored by the Endocrine Society, American Society for Reproductive Medicine, and European Society of Human Reproduction and Embryology) no longer lists LH/FSH ratio as a diagnostic criterion, but it remains a clinically useful pattern when interpreted alongside anti-Müllerian hormone, androgens, and ultrasound findings [9].

Perimenopause and Menopause Transition

FSH elevation above 25 IU/L on two tests drawn at least 4 to 6 weeks apart, with concurrent menstrual irregularity, defines the late menopause transition per STRAW+10. LH rises in parallel but is a secondary marker. Postmenopausal LH values typically run 15 to 54 IU/L. Values above 60 to 70 IU/L in a postmenopausal woman without a known cause merit pituitary imaging to rule out a gonadotroph adenoma.

Primary vs. Secondary Hypogonadism: The Diagnostic Algorithm LH Anchors

The single most important clinical use of LH is distinguishing primary from secondary hypogonadism. The algorithm is straightforward.

Step 1: Confirm low testosterone on two fasting morning samples (total testosterone <264 ng/dL in men per Endocrine Society 2018 [4]).

Step 2: Check LH (and FSH).

• LH elevated (above upper normal): primary hypogonadism. The gonads are failing; the pituitary is responding correctly.
• LH low or inappropriately normal: secondary hypogonadism. The hypothalamus or pituitary is not generating adequate drive.

Step 3: If secondary, check prolactin, iron studies (hemochromatosis), and, if prolactin is elevated or imaging is warranted, obtain a pituitary MRI with gadolinium.

This classification drives treatment choice. Primary hypogonadism in men is treated with testosterone replacement. Secondary hypogonadism, particularly in men who want to preserve fertility, may be treated with clomiphene citrate or hCG to stimulate endogenous LH and testosterone production rather than exogenous testosterone, which suppresses LH further.

Clomiphene Citrate and LH Stimulation Testing

Clomiphene citrate (Clomid) blocks estrogen receptors at the hypothalamus, removing negative feedback and raising LH and FSH. A meta-analysis of 18 trials (N=741) found clomiphene raised total testosterone from a mean of 228 ng/dL to 439 ng/dL while preserving spermatogenesis [10]. LH typically rises from baseline within 2 to 4 weeks of 25 to 50 mg daily dosing. A target post-clomiphene LH of 5 to 12 IU/L with concurrent testosterone normalization suggests an intact HPG axis and functional reserve.

hCG and the LH Receptor

Human chorionic gonadotropin (hCG) is structurally similar to LH and binds the same receptor on Leydig cells. In TRT protocols, hCG at 500 to 1,000 IU given two to three times per week maintains testicular volume and intratesticular testosterone when exogenous testosterone has suppressed endogenous LH [11]. Because hCG acts downstream of LH, it does not raise serum LH. Clinicians co-administering hCG should not expect LH normalization on labs; exogenous LH-receptor stimulation is occurring below the measurement point.

Longevity-Specific Considerations: Where the Evidence Points

The longevity-medicine framing of LH targets is built on three converging lines of evidence.

Testosterone Adequacy as a Longevity Signal

Low testosterone in men associates with higher all-cause mortality. A prospective cohort of 858 men followed for 11.8 years found that those with testosterone below 8.7 nmol/L (251 ng/dL) had significantly higher cardiovascular and total mortality compared to those above that threshold (P<0.001) [12]. Because LH is the upstream driver of testosterone, chronically elevated LH (8 to 9 IU/L) with borderline testosterone suggests the testes are working at their physiologic limit. That compensated state may still meet standard "normal" criteria while representing meaningful gonadal aging.

A longevity-medicine target of LH 3.0 to 7.0 IU/L in men is anchored to the mid-range of population normal, where the pituitary is not straining and the gonadal response is adequate. If free testosterone falls below the optimal zone (roughly 70 to 100 pg/mL on the Vermeulen calculated method) despite an LH already in the upper third of normal, clinical intervention becomes more defensible.

Sleep, Cortisol, and GnRH Suppression

Chronic sleep deprivation below six hours per night reduces testosterone by 10 to 15 percent and blunts LH pulsatility. A randomized crossover study of 10 healthy young men found that restricting sleep to five hours per night for one week reduced daytime testosterone by 10 to 15 percent [13]. Longevity protocols that address sleep architecture before initiating TRT are not merely conservative; they are clinically rational, because normalizing sleep may restore LH pulsatility and endogenous testosterone without pharmacologic intervention.

The Role of Metabolic Health

Adipose tissue aromatizes testosterone to estradiol. Elevated estradiol feeds back to suppress GnRH and LH. Men with obesity frequently show an LH in the low-to-normal range (2 to 4 IU/L) alongside low testosterone, a pattern that mimics secondary hypogonadism but is metabolically mediated. Weight loss of 10 percent body weight raises testosterone by approximately 2 to 3 nmol/L and modestly raises LH as central suppression lifts [14]. A GLP-1 receptor agonist such as semaglutide 2.4 mg (Wegovy), which produced 14.9 percent mean weight loss at 68 weeks in STEP-1 (N=1,961) [15], may therefore indirectly improve LH and testosterone without direct endocrine intervention.

Interpreting LH in Context of Other Labs

LH does not stand alone. Interpreting it requires at minimum:

• Total testosterone and free testosterone (calculated or equilibrium dialysis)
• FSH (together with LH, separates pituitary from gonadal disease)
• Prolactin (elevated prolactin suppresses GnRH)
• SHBG (binds testosterone; affects free fraction)
• Estradiol (in men: elevated estradiol suppresses LH; in women: tracks follicular development)

The Endocrine Society 2010 guideline on evaluation of male hypogonadism states: "Measurement of serum LH and FSH levels is recommended to distinguish primary from secondary hypogonadism in men with documented low testosterone." [4] Without LH, a low testosterone result cannot be fully interpreted.

In women with irregular cycles, a day 2 to 3 panel should include LH, FSH, estradiol, and anti-Müllerian hormone. The American Society for Reproductive Medicine notes that FSH above 10 IU/L or an AMH below 0.5 ng/mL on day 3 suggests diminished ovarian reserve, a finding that often co-occurs with rising LH [16].

Confounders That Shift LH

Several factors push LH outside its expected range without reflecting true HPG pathology:

• Recent vigorous exercise raises LH transiently for 30 to 90 minutes.
• Acute illness suppresses LH (part of the sick-euthyroid/sick-gonadal response).
• Exogenous estrogen (oral contraceptives, HRT) suppresses LH to near zero in women.
• GnRH agonists (leuprolide) initially spike, then suppress LH after 2 to 4 weeks via receptor downregulation.
• Anabolic steroids suppress LH, often to undetectable levels (<0.5 IU/L).

Documenting all medications and timing the draw appropriately eliminates most confounders before the result reaches clinical interpretation.

How to Order and Report LH Correctly

Specimen and Timing Requirements

• Men: Fasting morning draw, before 10 a.m. Collect on two separate days if testosterone is borderline low.
• Premenopausal women: Document cycle day on the requisition. Follicular baseline = days 2 to 5. Ovulation confirmation = days 12 to 16 (cycle-dependent).
• Postmenopausal women: Timing is less critical; LH is tonically elevated.
• Tube type: Serum separator tube (SST/gold top) is standard; some labs accept lithium heparin plasma.
• Stability: Stable at 4°C for 48 hours; freeze at -20°C for longer storage.

Reporting LH in a Clinical Note

A complete LH interpretation in a clinical note should include the numeric value, the assay reference range used, cycle phase or menopausal status, concurrent testosterone and FSH values, and a clinical interpretation sentence. "LH 7.8 IU/L (ref 1.5 to 9.3) with total testosterone 298 ng/dL suggests compensated primary hypogonadism; FSH 11.2 IU/L is mildly elevated. Recommend repeat morning fasting testosterone with SHBG and prolactin before initiating therapy" is the minimum clinical documentation standard.